{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:31:48Z","timestamp":1791952308442,"version":"4.3.4"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T00:00:00Z","timestamp":1566518400000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100010318","name":"University of Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010408","name":"Diagnostic Services Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010408","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Microbiology Laboratory"},{"DOI":"10.13039\/100004324","name":"Astellas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"The Medicines Company","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001316","name":"Abbott","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Achaogen"},{"name":"Cubist"},{"name":"Paladin Labs"},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen Ortho\/Ortho McNeil"},{"name":"Affinium"},{"name":"Basilea"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Paratek"},{"name":"Tetraphase"},{"name":"Theravance"},{"name":"Sanofi-Aventis and Zoetis"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The CANWARD surveillance study was established in 2007 to annually assess the in vitro susceptibilities of a variety of antimicrobial agents against bacterial pathogens isolated from patients receiving care in Canadian hospitals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>42\u2009936 pathogens were received and CLSI broth microdilution testing was performed on 37\u2009355 bacterial isolates. Limited patient demographic data submitted with each isolate were collated and analysed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the isolates tested, 43.5%, 33.1%, 13.2% and 10.2% were from blood, respiratory, urine and wound specimens, respectively; 29.9%, 24.8%, 19.0%, 18.1% and 8.2% of isolates were from patients in medical wards, emergency rooms, ICUs, hospital clinics and surgical wards. Patient demographics associated with the isolates were: 54.6% male\/45.4% female; 13.1% patients aged \u226417\u2009years, 44.3% 18\u201364\u2009years and 42.7% \u226565\u2009years. The three most common pathogens were Staphylococcus aureus (21.2%, both methicillin-susceptible and MRSA), Escherichia coli (19.6%) and Pseudomonas aeruginosa (9.0%). E. coli were most susceptible to meropenem and tigecycline (99.9%), ertapenem and colistin (99.8%), amikacin (99.7%) and ceftolozane\/tazobactam and plazomicin (99.6%). Twenty-three percent of S. aureus were MRSA. MRSA were most susceptible to ceftobiprole, linezolid and telavancin (100%), daptomycin (99.9%), vancomycin (99.8%) and tigecycline (99.2%). P. aeruginosa were most susceptible to ceftolozane\/tazobactam (98.3%) and colistin (95.0%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The CANWARD surveillance study has provided 10\u2009years of reference antimicrobial susceptibility testing data on pathogens commonly causing infections in patients attending Canadian hospitals.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkz283","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T18:05:04Z","timestamp":1561485904000},"page":"iv5-iv21","source":"Crossref","is-referenced-by-count":65,"title":["42936 pathogens from Canadian hospitals: 10 years of results (2007\u201316) from the CANWARD surveillance study"],"prefix":"10.1093","volume":"74","author":[{"given":"George G","family":"Zhanel","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada"},{"name":"Department of Medicine, Health Sciences Centre, 820 Sherbrook Street, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J","family":"Adam","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada"},{"name":"Clinical Microbiology, Health Sciences Centre\/Diagnostic Services, Shared Health, MS673-820 Sherbrook Street, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie R","family":"Baxter","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Fuller","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, Victoria Hospital, Room B10-117, London, Ontario, Canada"},{"name":"Division of Microbiology, London Health Sciences Centre, 800 Commissioners Road East, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A","family":"Nichol","sequence":"additional","affiliation":[{"name":"Clinical Microbiology, Health Sciences Centre\/Diagnostic Services, Shared Health, MS673-820 Sherbrook Street, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Denisuik","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa R","family":"Golden","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Hink","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe R S","family":"Lagac\u00e9-Wiens","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada"},{"name":"Clinical Microbiology, St. Boniface Hospital\/Diagnostic Services, Shared Health Manitoba, L4025-409 Tach\u00e9 Avenue, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Walkty","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada"},{"name":"Department of Medicine, Health Sciences Centre, 820 Sherbrook Street, Winnipeg, Manitoba, Canada"},{"name":"Clinical Microbiology, Health Sciences Centre\/Diagnostic Services, Shared Health, MS673-820 Sherbrook Street, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Mulvey","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada"},{"name":"National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Schweizer","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada"},{"name":"Department of Chemistry, University of Manitoba, 360 Parker Building, 144 Dysart Road, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denice","family":"Bay","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl J","family":"Hoban","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada"},{"name":"Clinical Microbiology, Health Sciences Centre\/Diagnostic Services, Shared Health, MS673-820 Sherbrook Street, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A","family":"Karlowsky","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada"},{"name":"Clinical Microbiology, St. Boniface Hospital\/Diagnostic Services, Shared Health Manitoba, L4025-409 Tach\u00e9 Avenue, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G","family":"Zhanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl J","family":"Hoban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie R","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A","family":"Nichol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe R S","family":"Lagac\u00e9-Wiens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Walkty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Blondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Slinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Zhanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Hoban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Delport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Laverdi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Poutanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Roscoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Matukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Goyette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Carignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Bergevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,23]]},"reference":[{"key":"2019091012413664600_dkz283-B1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1473-3099(06)70689-2","article-title":"Anti-infectives research and development problems, challenges, and solutions","volume":"7","author":"Bradley","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"2019091012413664600_dkz283-B2","doi-asserted-by":"crossref","first-page":"k462.","DOI":"10.1136\/bmj.k462","article-title":"First WHO antimicrobial surveillance data reveal high levels of resistance globally","volume":"360","author":"Mayor","year":"2018","journal-title":"BMJ"},{"key":"2019091012413664600_dkz283-B3","first-page":"136","article-title":"Antimicrobial susceptibility trends and evolution of isolates with extended spectrum \u03b2-lactamases among Gram-negative organisms recovered during the SMART study in Spain (2011\u20132015","volume":"31","author":"Canton","year":"2018","journal-title":"Rev Esp Quimioter"},{"key":"2019091012413664600_dkz283-B4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3201\/eid2404.171461","article-title":"Carbapenem-nonsusceptible Acinetobacter baumannii, 8 US metropolitan areas, 2012\u20132015","volume":"24","author":"Bulens","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"2019091012413664600_dkz283-B5","first-page":"1","article-title":"Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin, and ceftazidime-avibactam - epidemiology laboratory detection and treatment implications","volume":"21","author":"Sherry","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2019091012413664600_dkz283-B6","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jac\/dkx471","article-title":"Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK Infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-UK)","volume":"73","author":"Woodford","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019091012413664600_dkz283-B7","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/jac\/dky027","article-title":"Treatment of infections caused by multidrug resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy\/Healthcare Infection Society\/British Infection Association Joint Working Party","volume":"73","author":"Hawkey","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019091012413664600_dkz283-B8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.coph.2017.10.009","article-title":"The application of in vitro surveillance data for antibacterial dose selection","volume":"36","author":"Flamm","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"2019091012413664600_dkz283-B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/microbiolspec.ARBA-0009-2017","article-title":"Antimicrobial resistance: a One Health perspective","volume":"6","author":"McEwen","year":"2018","journal-title":"Microbiol Spectr"},{"key":"2019091012413664600_dkz283-B10","doi-asserted-by":"crossref","DOI":"10.1007\/s10393-018-1325-6","article-title":"Prioritizing One Health approach in the immediate fight against antimicrobial resistance","author":"Ogawa","year":"2018","journal-title":"Ecohealth"},{"key":"2019091012413664600_dkz283-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpubh.2018.00046","article-title":"Networking of public health microbiology laboratories bolsters Europe\u2019s defenses against infectious diseases","volume":"6","author":"Albiger","year":"2018","journal-title":"Front Publ Health"},{"key":"2019091012413664600_dkz283-B12","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1073\/pnas.1717295115","article-title":"Global increase and geographic convergence in antibiotic consumption between 2000 and 2015","volume":"115","author":"Klein","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019091012413664600_dkz283-B13","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/cid\/cix1093","article-title":"Infectious diseases physicians: leading the way in antimicrobial stewardship","volume":"66","author":"Ostrowsky","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019091012413664600_dkz283-B14","doi-asserted-by":"crossref","first-page":"i7","DOI":"10.1093\/jac\/dkt022","article-title":"Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007\u201311 study","volume":"68","author":"Zhanel","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2019091012413664600_dkz283-B15","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically\u2014Eleventh Edition: Approved Standard M07-A11","year":"2018"},{"key":"2019091012413664600_dkz283-B16","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Twenty-Eighth Informational Supplement: M100-S28.","year":"2018"},{"key":"2019091012413664600_dkz283-B17","doi-asserted-by":"crossref","first-page":"i47","DOI":"10.1093\/jac\/dkt026","article-title":"Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada","volume":"68","author":"Nichol","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2019091012413664600_dkz283-B18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/2008\/754249","article-title":"A preliminary guideline for the assignment of methicillin-resistant Staphylococcus aureus to a Canadian pulsed-field gel electrophoresis epidemic type using spa typing","volume":"19","author":"Golding","year":"2008","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2019091012413664600_dkz283-B19","doi-asserted-by":"crossref","first-page":"i57","DOI":"10.1093\/jac\/dkt027","article-title":"Molecular epidemiology of extended-spectrum \u03b2-lactamase, AmpC \u03b2-lactamase and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007\u201311","volume":"68","author":"Denisuik","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2019091012413664600_dkz283-B20","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1128\/AAC.00384-15","article-title":"Epidemiology of vancomycin-resistant enterococci in Canadian hospitals (CANWARD study, 2007 to 2013)","volume":"59","author":"Simner","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019091012413664600_dkz283-B21","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1128\/AAC.00881-16","article-title":"Activities of tedizolid and linezolid determined by the reference broth microdilution method against 3,032 Gram-positive bacterial isolates collected in Asia-Pacific, Eastern Europe and Latin American countries in 2014","volume":"60","author":"Pfaller","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019091012413664600_dkz283-B22","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/jac\/dkw052","article-title":"Surveillance of linezolid resistance via the Zyvox annual appraisal of potency and spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates","volume":"71","author":"Mendes","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2019091012413664600_dkz283-B23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2017.12.020","article-title":"Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015)","volume":"91","author":"Pfaller","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019091012413664600_dkz283-B24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1179\/1973947815Y.0000000050","article-title":"Telavancin activity tested against Gram-positive clinical isolates from European, Russian, and Israeli hospitals (2011\u20132013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin","volume":"28","author":"Mendes","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2019091012413664600_dkz283-B25","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/jac\/dkw319","article-title":"Longitudinal (2010\u20132014) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010\u20132013) analysis of oritavancin in vitro potency","volume":"71","author":"Mendes","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2019091012413664600_dkz283-B26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40265-015-0352-7","article-title":"Tedizolid: a novel oxazolidinone with enhanced potency against multi-drug resistant Gram-positive pathogens","volume":"75","author":"Zhanel","year":"2015","journal-title":"Drugs"},{"key":"2019091012413664600_dkz283-B27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jgar.2015.04.003","article-title":"Analysis of 5 year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009\u20132013)","volume":"3","author":"Sader","year":"2015","journal-title":"J Glob Antimicrob Resist"},{"key":"2019091012413664600_dkz283-B28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.diagmicrobio.2017.03.003","article-title":"Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations","volume":"88","author":"Jones","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019091012413664600_dkz283-B29","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1093\/cid\/civ534","article-title":"Telavancin: mechanisms of action, in vitro activity and mechanisms of resistance","volume":"61","author":"Karlowsky","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019091012413664600_dkz283-B30","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ijantimicag.2018.01.006","article-title":"Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016)","volume":"51","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2019091012413664600_dkz283-B31","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/jac\/dkx261","article-title":"In vitro activity of plazomicin against \u03b2-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE)","volume":"72","author":"Zhang","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2019091012413664600_dkz283-B32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1586\/eri.12.25","article-title":"Comparison of the next generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin","volume":"10","author":"Zhanel","year":"2012","journal-title":"Exp Rev Antiinfect Ther"},{"key":"2019091012413664600_dkz283-B33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jac\/dkx468","article-title":"In vitro activity of ceftolozane\/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008\u201316","volume":"73","author":"Walkty","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019091012413664600_dkz283-B34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00128071-200809040-00004","article-title":"Ceftobiprole: a review of a broad spectrum and anti-MRSA cephalosporin","volume":"9","author":"Zhanel","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"2019091012413664600_dkz283-B35","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1128\/AAC.00077-06","article-title":"Antimicrobial activity and spectrum of cefovecin, a new extended- spectrum cephalosporin, against pathogens collected from dogs and cats in Europe and North America","volume":"50","author":"Stegemann","year":"2006","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/Supplement_4\/iv5\/29198062\/dkz283.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T14:37:15Z","timestamp":1590071835000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/Supplement_4\/iv5\/5553077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":35,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2019,8,23]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz283","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,8,1]]}}}